BR0115938A - Derivados de guanidina e amidina com inibidores do fator xa - Google Patents
Derivados de guanidina e amidina com inibidores do fator xaInfo
- Publication number
- BR0115938A BR0115938A BR0115938-0A BR0115938A BR0115938A BR 0115938 A BR0115938 A BR 0115938A BR 0115938 A BR0115938 A BR 0115938A BR 0115938 A BR0115938 A BR 0115938A
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- compounds
- inhibitors
- formula
- guanidine
- Prior art date
Links
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title abstract 4
- 229940123583 Factor Xa inhibitor Drugs 0.000 title abstract 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001409 amidines Chemical class 0.000 title abstract 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 title abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
"DERIVADOS DE GUANIDINA E AMIDINA COMO INIBIDORES DO FATOR XA". A presente invenção refere-se a compostos da fórmula I, onde R~ 0~, Q, X, Q, D, R~ 10~ e V têm os significados indicados nas reivindicações. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles apresentam um forte efeito antitrombótico e são adequados, por exemplo, para a terapia e a profilaxia de distúrbios cardiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coagulação do sangue fator Xa (FXa) e/ou fator Vlla (FVlla), e em geral podem ser aplicados em condições em que esteja presente uma atividade indesejada do fator Xa e/ou do fator Vlla ou para cuja cura ou prevenção se deseja uma inibição do fator Xa e/ou do fator Vlla. A invenção referese ainda a processos para a preparação de compostos da fórmula (I), seus uso, em particular como ingredientes ativos em farmacêuticos, e preparados farmacêuticos compreendendo os mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00126750 | 2000-12-06 | ||
| PCT/EP2001/013874 WO2002046159A1 (en) | 2000-12-06 | 2001-11-28 | Guanidine and amidine derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0115938A true BR0115938A (pt) | 2003-12-23 |
Family
ID=8170585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0115938-0A BR0115938A (pt) | 2000-12-06 | 2001-11-28 | Derivados de guanidina e amidina com inibidores do fator xa |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20020173656A1 (pt) |
| EP (1) | EP1345900B1 (pt) |
| JP (1) | JP4274522B2 (pt) |
| KR (1) | KR20040015036A (pt) |
| CN (1) | CN1479722A (pt) |
| AR (1) | AR033684A1 (pt) |
| AU (2) | AU2002233206B2 (pt) |
| BR (1) | BR0115938A (pt) |
| CA (1) | CA2430518C (pt) |
| CZ (1) | CZ20031554A3 (pt) |
| DE (1) | DE60126143T2 (pt) |
| DK (1) | DK1345900T3 (pt) |
| EE (1) | EE200300192A (pt) |
| ES (1) | ES2278798T3 (pt) |
| HR (1) | HRP20030447A2 (pt) |
| HU (1) | HUP0302604A3 (pt) |
| IL (2) | IL156214A0 (pt) |
| MX (1) | MXPA03004848A (pt) |
| NO (1) | NO20032489L (pt) |
| NZ (1) | NZ526269A (pt) |
| PL (1) | PL362320A1 (pt) |
| PT (1) | PT1345900E (pt) |
| RU (1) | RU2003120070A (pt) |
| SK (1) | SK6862003A3 (pt) |
| WO (1) | WO2002046159A1 (pt) |
| ZA (1) | ZA200303847B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265398A1 (en) * | 2002-08-09 | 2004-02-25 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7544699B2 (en) * | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| JP4794303B2 (ja) * | 2003-10-10 | 2011-10-19 | 中外製薬株式会社 | 固形腫瘍治療剤 |
| ATE483708T1 (de) | 2004-03-08 | 2010-10-15 | Prosidion Ltd | Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase |
| DE602005013275D1 (de) | 2004-12-02 | 2009-04-23 | Prosidion Ltd | Pyrrolopyridin-2-karbonsäureamide |
| DE102006048300A1 (de) * | 2006-01-26 | 2007-08-02 | Hellstern, Peter, Prof. Dr.med. | Inhibitoren des Blutgerinnungsfaktors Xa zur Verwendung als Antikoagulans |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| US8507640B2 (en) | 2010-08-19 | 2013-08-13 | International Business Machines Corporation | Methods of ring opening polymerization and catalysts therefor |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
| SG11202001684PA (en) | 2017-10-06 | 2020-03-30 | Forma Therapeutics Inc | Inhibiting ubiquitin specific peptidase 30 |
| ES2945834T3 (es) | 2018-10-05 | 2023-07-07 | Forma Therapeutics Inc | Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (pt) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| ES2103181B1 (es) * | 1994-08-01 | 1998-04-01 | Menarini Lab | Amidas naftalenicas con accion antagonista de los leucotrienos. |
| ATE262536T1 (de) * | 1994-04-26 | 2004-04-15 | Aventis Pharma Inc | Faktor xa inhibitoren |
| US5792769A (en) * | 1995-09-29 | 1998-08-11 | 3-Dimensional Pharmaceuticals, Inc. | Guanidino protease inhibitors |
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| TW542822B (en) * | 1997-01-17 | 2003-07-21 | Ajinomoto Kk | Benzamidine derivatives |
| IL133625A0 (en) * | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
| DE69919349T2 (de) * | 1998-03-23 | 2005-01-13 | Aventis Pharmaceuticals Inc. | Piperidinyl- und n-amidinopiperidinyl-derivate |
| US20020016339A1 (en) * | 1998-03-23 | 2002-02-07 | Klein Scott I. | Piperididinyl and N-amidinopiperidinyl derivatives |
| EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
| CZ2002961A3 (cs) * | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
-
2001
- 2001-11-28 DE DE60126143T patent/DE60126143T2/de not_active Expired - Lifetime
- 2001-11-28 HU HU0302604A patent/HUP0302604A3/hu unknown
- 2001-11-28 BR BR0115938-0A patent/BR0115938A/pt not_active Application Discontinuation
- 2001-11-28 MX MXPA03004848A patent/MXPA03004848A/es active IP Right Grant
- 2001-11-28 NZ NZ526269A patent/NZ526269A/en unknown
- 2001-11-28 DK DK01984775T patent/DK1345900T3/da active
- 2001-11-28 CN CNA018201121A patent/CN1479722A/zh active Pending
- 2001-11-28 KR KR10-2003-7007612A patent/KR20040015036A/ko not_active Application Discontinuation
- 2001-11-28 PL PL01362320A patent/PL362320A1/xx unknown
- 2001-11-28 ES ES01984775T patent/ES2278798T3/es not_active Expired - Lifetime
- 2001-11-28 JP JP2002547898A patent/JP4274522B2/ja not_active Expired - Fee Related
- 2001-11-28 AU AU2002233206A patent/AU2002233206B2/en not_active Ceased
- 2001-11-28 CA CA2430518A patent/CA2430518C/en not_active Expired - Fee Related
- 2001-11-28 PT PT01984775T patent/PT1345900E/pt unknown
- 2001-11-28 SK SK686-2003A patent/SK6862003A3/sk unknown
- 2001-11-28 RU RU2003120070/04A patent/RU2003120070A/ru not_active Application Discontinuation
- 2001-11-28 IL IL15621401A patent/IL156214A0/xx unknown
- 2001-11-28 WO PCT/EP2001/013874 patent/WO2002046159A1/en active IP Right Grant
- 2001-11-28 EP EP01984775A patent/EP1345900B1/en not_active Expired - Lifetime
- 2001-11-28 CZ CZ20031554A patent/CZ20031554A3/cs unknown
- 2001-11-28 EE EEP200300192A patent/EE200300192A/xx unknown
- 2001-11-28 AU AU3320602A patent/AU3320602A/xx active Pending
- 2001-12-04 AR ARP010105642A patent/AR033684A1/es unknown
- 2001-12-06 US US10/004,422 patent/US20020173656A1/en not_active Abandoned
-
2003
- 2003-05-19 ZA ZA200303847A patent/ZA200303847B/en unknown
- 2003-05-29 IL IL156214A patent/IL156214A/en not_active IP Right Cessation
- 2003-06-02 NO NO20032489A patent/NO20032489L/no not_active Application Discontinuation
- 2003-06-04 HR HR20030447A patent/HRP20030447A2/hr not_active Application Discontinuation
-
2004
- 2004-07-07 US US10/886,312 patent/US7435747B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0116473A (pt) | Derivados de oxibenzamidas como inibidores de fator xa | |
| BR0214396A (pt) | Indol-2-carboxamidas como inibidores de fator xa | |
| BR0317659A (pt) | Derivados de pirazol como inibidores de fator xa | |
| BR0111264A (pt) | Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização | |
| BRPI0508048A (pt) | derivados de pirrol como inibidores do fator xa | |
| BR0115938A (pt) | Derivados de guanidina e amidina com inibidores do fator xa | |
| BRPI0508320A (pt) | derivados de beta-aminoácido como inibidores do fator xa | |
| BR0313240A (pt) | Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos | |
| TW200510400A (en) | Indazole-derivatives as factor Xa inhibitors | |
| PE20050156A1 (es) | DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa | |
| IL171843A (en) | TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS | |
| MXPA03011022A (es) | Derivados de urea con actividad antiproteolitica. | |
| BR0015186A (pt) | N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as | |
| BR0011461A (pt) | Inibidores do fator viia | |
| TNSN05297A1 (en) | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| BR0317003A (pt) | Derivados de imidazol como inibidores do fator xa | |
| ECSP056179A (es) | Derivados de azaindol como inhibidores del factor xa | |
| BR0207981A (pt) | Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |